Searched for: author%3A%22van+den+Hoek%2C+A.M.%22
(1 - 20 of 38)

Pages

document
van den Hoek, A.M. (author), Özsezen, S. (author), Caspers, M.P.M. (author), van Koppen, A. (author), Hanemaaijer, R. (author), Verschuren, L. (author)
The prevalence of non-alcoholic steatohepatitis (NASH) is rapidly increasing and associated with cardiovascular disease (CVD), the major cause of mortality in NASH patients. Although sharing common risk factors, the mechanisms by which NASH may directly contribute to the development to CVD remain poorly understood. The aim of this study is to...
article 2022
document
Jong, J.C.B.C. (author), Attema, B.J. (author), van der Hoek, M.D. (author), Verschuren, L. (author), Caspers, M.P.M. (author), Kleemann, R. (author), van der Leij, F.R. (author), van den Hoek, A.M. (author), Nieuwenhuizen1, A.G. (author), Keijer, J. (author)
Sex differences in muscle‐ageing are incompletely understood and could be crucial for the optimalisation of sarcopenia‐related interventions. • Therefore, we performed an observational trial to gain insight in potential sex differences in processes involved in human muscle‐ageing.
public lecture 2022
document
van Bilsen, J.H.M. (author), van den Brink, W. (author), van den Hoek, A.M. (author), Dulos, R. (author), Caspers, M.P.M. (author), Kleeman, R. (author), Wopereis, S. (author), Verschuren, L. (author)
Metabolic disorders, such as obesity and type 2 diabetes have a large impact on global health, especially in industrialized countries. Tissue-specific chronic low-grade inflammation is a key contributor to complications in metabolic disorders. To support therapeutic approaches to these complications, it is crucial to gain a deeper understanding...
article 2021
document
van den Hoek, A.M. (author), Verschuren, L. (author), Caspers, M.P.M. (author), Worms, N. (author), Menke, A.L. (author), Princen, H.M.G. (author)
Non-alcoholic steatohepatitis (NASH) is the most rapidly growing liver disease that is nevertheless without approved pharmacological treatment. Despite great effort in developing novel NASH therapeutics, many have failed in clinical trials. This has raised questions on the adequacy of preclinical models. Elafibranor is one of the drugs currently...
article 2021
document
van den Hoek, A.M. (author), de Jong, J.C.B.C. (author), Worms, N. (author), van Nieuwkoop, A. (author), Voskuilen, M. (author), Menke, A.L. (author), Lek, S. (author), Caspers, M.P.M. (author), Verschuren, L. (author), Kleemann, R. (author)
Background. Non-alcoholic steatohepatitis (NASH) has become one of the most common liver diseases and is still without approved pharmacotherapy. Lifestyle interventions using exercise and diet change remain the current treatment of choice and even a small weight loss (5–7%) can already have a beneficial effect on NASH. However, the underlying...
article 2021
document
van der Hoek, M.D. (author), Nieuwenhuizen, A.G. (author), Kuda, O. (author), Bos, P. (author), Paluchova, V. (author), Verschuren, L. (author), van den Hoek, A.M. (author), Kleemann, R. (author), Veeger, N.J.G.M. (author), van der Leij, F.R. (author), Keijer, J. (author)
This study tested the hypothesis that in human aging, a decreased intramuscular acylcarnitine status is associated with (pre-)frailty, reduced physical performance, and altered mitochondrial function. We used a cross-sectional study design with well-matched fit and (pre-)frail old males and females, using young males and females as healthy...
article 2020
document
Stokman, G. (author), van den Hoek, A.M. (author), Denker Thorbekk, D. (author), Pieterman, E.J. (author), Skovgård Veidal, S. (author), Basta, B. (author), Iruarrizaga-Lejarreta, M. (author), van der Hoorn, J.W. (author), Verschuren, L. (author), Berbée, J.F.P. (author), Rensen, P.C.N. (author), Skjæret, T. (author), Alonso, C. (author), Feigh, M. (author), Kastelein, J.J.P. (author), Friedman, S.L. (author), Princen, H.M.G. (author), Fraser, D.A. (author)
article 2020
document
van den Hoek, A.M. (author), Verschuren, L. (author), Worms, N. (author), van Nieuwkoop, A. (author), de Ruiter, C. (author), Attema, J. (author), Menke, A.L. (author), Caspers, M.P.M. (author), Radhakrishnan, S. (author), Salic, K. (author), Kleemann, R. (author)
Non-alcoholic steatohepatitis (NASH) is a fast-growing liver disorder that is associated with an increased incidence of cardiovascular disease and type 2 diabetes. Animal models adequately mimicking this condition are scarce. We herein investigate whether Ldlr−/−. Leiden mice on different high-fat diets represent a suitable NASH model. Ldlr−/−....
article 2020
document
van den Hoek, A.M. (author), Pieterman, E.J. (author), van der Hoorn, J.W. (author), Iruarrizaga-Lejarreta, M. (author), Alonso, C. (author), Verschuren, L. (author), Skjæret, T. (author), Princen, H.M.G. (author), Fraser, D.A. (author)
Icosabutate is a structurally engineered eicosapentaenoic acid derivative under development for nonalcoholic steatohepatitis (NASH). In this study, we investigated the absorption and distribution properties of icosabutate in relation to liver targeting and used rodents to evaluate the effects of icosabutate on glucose metabolism, insulin...
article 2020
document
Pouwer, M.G. (author), Heinonen, S.E. (author), Behrendt, M. (author), Andréasson, A.M. (author), Koppen A. van, (author), Menke, A.L. (author), Pieterman, E.J. (author), van den Hoek, A.M. (author), Jukema, J.W. (author), Leighton, B. (author), Jonsson-Rylander, A.M. (author), Princen, H.M.G. (author)
Background. There is a lack of predictive preclinical animal models combining atherosclerosis and type 2 diabetes. APOE*3-Leiden (E3L) mice are a well-established model for diet-induced hyperlipidemia and atherosclerosis, and glucokinase+/− (GK+/−) mice are a translatable disease model for glucose control in type 2 diabetes. The respective mice...
article 2019
document
van den Hoek, A.M. (author), Zondag, G.C.M. (author), Verschuren, L. (author), de Ruiter, C. (author), Attema, J. (author), de Wit, E.C. (author), Schwerk, A.M.K. (author), Guigas, B. (author), Rietman, A. (author), Strijker, R. (author), Kleemann, R. (author)
BACKGROUND: Muscle atrophy is defined as decreased muscle mass, associated with aging as well as with various chronic diseases and is a fundamental cause of frailty, functional decline and disability. Frailty represents a huge potential public health issue worldwide with high impact on healthcare costs. A major clinical issue is therefore to...
article 2019
document
Kozijn, A.E. (author), Gierman, L.M. (author), van der Ham, F. (author), Mulder, P. (author), Morrison, M.C. (author), Kühnast, S. (author), van der Heijden, R.A. (author), Stavro, P.M. (author), van Koppen, A. (author), Pieterman, E.J. (author), van den Hoek, A.M. (author), Kleemann, R. (author), Princen, H.M.G. (author), Mastbergen, S.C. (author), Lafeber, F.P.J.G. (author), Zuurmond, A.M. (author), Bobeldijk, I. (author), Weinans, H. (author), Stoop, R. (author)
Objective. Human cohort studies have demonstrated a role for systemic metabolic dysfunction in osteoarthritis (OA) pathogenesis in obese patients. To explore the mechanisms underlying this metabolic phenotype of OA, we examined cartilage degradation in the knees of mice from different genetic backgrounds in which a metabolic phenotype was...
article 2018
document
Morrison, M.C. (author), Verschuren, L. (author), Salic, K. (author), Verhij, J. (author), Menke, A. (author), Wielinga, P.Y. (author), Iruarrizaga-Lejarretts, M. (author), Gole, L. (author), Yu, W.M. (author), Turner, S. (author), Caspers, M.P.M. (author), Martinez-Arranz, I. (author), Pieterman, E. (author), Stoop, R. (author), van Koppen, A. (author), van den Hoek, A.M. (author), Mato, J.M. (author), Hanemaaijer, R. (author), Alonso, C. (author), Kleemann, R. (author)
Concerns have been raised about whether preclinical models sufficiently mimic molecular disease processes observed in nonalcoholic steatohepatitis (NASH) patients, bringing into question their translational value in studies of therapeutic interventions in the process of NASH/fibrosis. We investigated the representation of molecular disease...
article 2018
document
Dewey, F.E. (author), Gusarova, V. (author), Dunbar, R.L. (author), O'Dushlaine, C. (author), Schurmann, C. (author), Gottesman, O. (author), McCarthy, S. (author), van Hout, C.V. (author), Bruse, S. (author), Dansky, H.M. (author), Leader, J.B. (author), Murray, M.F. (author), Ritchie, M.D. (author), Kirchner, H.L. (author), Habegger, L. (author), Lopez, A. (author), Penn, J. (author), Zhao, A. (author), Shao, W. (author), Stahl, N. (author), Murphy, A.J. (author), Hamon, S. (author), Bouzelmat, A. (author), Zhang, R. (author), Shumel, B. (author), Pordy, R. (author), Gipe, D. (author), Herman, G.A. (author), Sheu, W.H.H. (author), Lee, I.T. (author), Liang, K.W. (author), Guo, X. (author), Rotter, J.I. (author), Chen, Y.I. (author), Kraus, W.E. (author), Shah, S.H. (author), Damrauer, S. (author), Small, A. (author), Rader, D.J. (author), Wulff, A.B. (author), Nordestgaard, B.G. (author), Tybjærg-Hansen, A. (author), van den Hoek, A.M. (author), Princen, H.M.G. (author), Ledbetter, D.H. (author), Carey, D.J. (author), Overton, J.D. (author), Reid, J.G. (author), Sasiela, W.J. (author), Banerjee, P. (author), Shuldiner, A.R. (author), Borecki, I.B. (author), Teslovich, T.M. (author), Yancopoulos, G.D. (author), Mellis, S.J. (author), Gromada, J. (author), Baras, A. (author)
Background Loss-of-function variants in the angiopoietin-like 3 gene (ANGPTL3) have been associated with decreased plasma levels of triglycerides, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol. It is not known whether such variants or therapeutic antagonism of ANGPTL3 are associated with a reduced risk...
article 2017
document
van Koppen, A. (author), Verschuren, L. (author), van den Hoek, A.M. (author), Verheij, J. (author), Morrison, M.C. (author), Li, K. (author), Nagabukuro, H. (author), Costessi, A. (author), Caspers, M.P.M. (author), van den Broek, T.J. (author), Sagartz, J. (author), Kluft, C. (author), Beysen, C. (author), Emson, C. (author), van Gool, A.J. (author), Goldschmeding, R. (author), Stoop, R. (author), Bobeldijk-Pastorova, I. (author), Turner, S.M. (author), Hanauer, G. (author), Hanemaaijer, R. (author)
Background & Aims: The incidence of nonalcoholic steatohepatitis (NASH) is increasing. The pathophysiological mechanisms of NASH and the sequence of events leading to hepatic fibrosis are incompletely understood. The aim of this study was to gain insight into the dynamics of key molecular processes involved in NASH and to rank early markers for...
article 2017
document
Mulder, P. (author), van den Hoek, A.M. (author), Kleenann, R. (author)
Background and aim. Obese patients with chronic inflammation in white adipose tissue (WAT) have an increased risk of developing non-alcoholic steatohepatitis (NASH). The C-C chemokine receptor-2 (CCR2) has a crucial role in the recruitment of immune cells to WAT and liver, thereby promoting the inflammatory component of the disease. Herein, we...
article 2017
document
Liang, W. (author), Verschuren, L. (author), Mulder, P. (author), van der Hoorn, J.W.A. (author), Verheij, J. (author), van Dam, A.D. (author), Boon, M.R. (author), Princen, H.M.G. (author), Havekes, L.M. (author), Kleemann, R. (author), van den Hoek, A.M. (author)
BACKGROUND AND PURPOSE: Salsalate (salicylsalicylic acid) is an anti-inflammatory drug that was recently found to exert beneficial metabolic effects on glucose and lipid metabolism. Although its utility in the prevention and management of a wide range of vascular disorders, including type 2 diabetes and metabolic syndrome has been suggested...
article 2015
document
van Dam, A.D. (author), Nahon, K.J. (author), Kooijman, S. (author), van den Berg, S.M. (author), Kanhai, A.A. (author), Kikuchi, T. (author), Heemskerk, M.M. (author), van Harmelen, V. (author), Lombès, M. (author), van den Hoek, A.M. (author), de Winther, M.P. (author), Lutgens, E. (author), Guigas, B. (author), Rensen, P.C. (author), Boon, M.R. (author)
Salsalate improves glucose intolerance and dyslipidemia in type 2 diabetes patients, but the mechanism is still unknown. The aim of the current study was to unravel the molecular mechanisms involved in these beneficial metabolic effects of salsalate by treating mice with salsalate during and after development of high-fat diet-induced obesity. We...
article 2015
document
Geerling, J.J. (author), Boon, M.R. (author), van der Zon, G.C. (author), van den Berg, S.A.A. (author), van den Hoek, A.M. (author), Lombès, M. (author), Princen, H.M.G. (author), Havekes, L.M. (author), Rensen, P.C.N. (author), Guigas, B. (author)
Metformin is the first-line drug for the treatment of type 2 diabetes. Besides its well-characterized antihyperglycemic properties, metformin also lowers plasma VLDL triglyceride (TG). In this study, we investigated the underlying mechanisms in APOE*3-Leiden.CETP mice, a well-established model for human-like lipoprotein metabolism. We found that...
article 2014
document
van den Hoek, A.M. (author), van der Hoorn, J.W.A. (author), Maas, A.C. (author), van den Hoogen, R.M. (author), van Nieuwkoop, A. (author), Droog, S. (author), Offerman, E.H. (author), Pieterman, E.J. (author), Havekes, L.M. (author), Princen, H.M.G. (author)
Aims: This study aimed to investigate systematically (i) the appropriate dietary conditions to induce the features of the MetS in APOE*3Leiden.humanCholesteryl Ester Transfer Protein (E3L.CETP) mice and (ii) whether the response of this model to different antidiabetic and hypolipidemic drugs is similar as in humans. Methods: Male obese, IR and...
article 2014
Searched for: author%3A%22van+den+Hoek%2C+A.M.%22
(1 - 20 of 38)

Pages